Dechra Pharmaceuticals PLC banner
D

Dechra Pharmaceuticals PLC
F:1PK

Watchlist Manager
Dechra Pharmaceuticals PLC
F:1PK
Watchlist
Price: 45.2 EUR Market Closed
Market Cap: €5.1B

Wall Street
Price Targets

1PK Price Targets Summary
Dechra Pharmaceuticals PLC

There are no price targets for 1PK.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Dechra Pharmaceuticals PLC Competitors:
Price Targets

Revenue
Forecast

18% / Year
Past Growth
9% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss
18% / Year
Past Growth
9% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss

For the last 8 years the compound annual growth rate for Dechra Pharmaceuticals PLC's revenue is 18%. The projected CAGR for the next 3 years is 9%.

Operating Income
Forecast

-1% / Year
Past Growth
98% / Year
Estimated Growth
Estimates Accuracy
-48%
Average Miss
-1% / Year
Past Growth
98% / Year
Estimated Growth
Estimates Accuracy
-48%
Average Miss

For the last 8 years the compound annual growth rate for Dechra Pharmaceuticals PLC's operating income is -1%. The projected CAGR for the next 3 years is 98%.

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-62%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-62%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is 1PK's stock price target?
Not Available

1PK doesn't have any price targets made by Wall Street professionals.

What is Dechra Pharmaceuticals PLC's Revenue forecast?
Projected CAGR
9%

For the last 8 years the compound annual growth rate for Dechra Pharmaceuticals PLC's revenue is 18%. The projected CAGR for the next 3 years is 9%.

What is Dechra Pharmaceuticals PLC's Operating Income forecast?
Projected CAGR
98%

For the last 8 years the compound annual growth rate for Dechra Pharmaceuticals PLC's operating income is -1%. The projected CAGR for the next 3 years is 98%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett